Johnson & Johnson Highlights P-III Clinical Data of Icotrokinra for Plaque Psoriasis at AAD 2025

Shots:

• J&J has reported P-III trial data incl. ICONIC-LEAD (vs PBO) & ICONIC-ADVANCE 1&2 (vs Sotyktu) assessing icotrokinra (JNJ-2113, QD, PO) to treat mod. to sev. plaque Ps
• OICONIC-LEAD showed that pts achieved IGA 0/1 (65% vs 8%) & reached PASI 90 (50% vs 4%) at 16wks. By Wk. 24, 74% achieved IGA 0/1, 65% reached PASI 90, & ~50% had completely clear skin (46% IGA 0 & 40% PASI100); data from subgroup (adolescent) analysis to be presented at future meeting
• Additionally, ICONIC-ADVANCE-1 & 2 met its co-1EPs (IGA 0/1 & PASI 90) at 16wks. & all 2EPs at Wks. 16-24, showing superiority to Sotyktu. Also, J&J will advance P-III (ICONIC-ASCEND) trial, comparing icotrokinra to Stelara & PBO

Ref: Johnson & Johnson | Image: Johnson & Johnson

Related News:- The US FDA Approves sNDA for J&J’s Spravato (esketamine) to Treat Major Depressive Disorder (MDD)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com